FI107879B - Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi - Google Patents

Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi Download PDF

Info

Publication number
FI107879B
FI107879B FI941133A FI941133A FI107879B FI 107879 B FI107879 B FI 107879B FI 941133 A FI941133 A FI 941133A FI 941133 A FI941133 A FI 941133A FI 107879 B FI107879 B FI 107879B
Authority
FI
Finland
Prior art keywords
thymosin
interferon
patients
hepatitis
treatment
Prior art date
Application number
FI941133A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI941133A0 (fi
FI941133A (fi
Inventor
Milton Mutchnick
Kenneth E Sherman
Paul Chretian
Original Assignee
Univ Wayne State
Alpha 1 Biomedicals Inc
Us Of America As By The Secret
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State, Alpha 1 Biomedicals Inc, Us Of America As By The Secret filed Critical Univ Wayne State
Publication of FI941133A0 publication Critical patent/FI941133A0/fi
Publication of FI941133A publication Critical patent/FI941133A/fi
Application granted granted Critical
Publication of FI107879B publication Critical patent/FI107879B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
FI941133A 1991-09-13 1994-03-10 Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi FI107879B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
US75954491 1991-09-13
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c
US9207556 1992-09-08

Publications (3)

Publication Number Publication Date
FI941133A0 FI941133A0 (fi) 1994-03-10
FI941133A FI941133A (fi) 1994-03-10
FI107879B true FI107879B (fi) 2001-10-31

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941133A FI107879B (fi) 1991-09-13 1994-03-10 Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi

Country Status (23)

Country Link
US (3) US6001799A (hu)
EP (1) EP0603305B1 (hu)
JP (1) JP3228512B2 (hu)
KR (1) KR100254082B1 (hu)
AT (1) ATE152914T1 (hu)
AU (1) AU667327B2 (hu)
CA (1) CA2119006C (hu)
CZ (1) CZ286827B6 (hu)
DE (1) DE69219782T2 (hu)
DK (1) DK0603305T3 (hu)
ES (1) ES2103966T3 (hu)
FI (1) FI107879B (hu)
GR (1) GR3024025T3 (hu)
HK (1) HK1021687A1 (hu)
HU (1) HU221006B1 (hu)
MX (1) MX9205240A (hu)
NO (1) NO941310L (hu)
RO (1) RO111991B1 (hu)
RU (1) RU2104010C1 (hu)
SG (1) SG64897A1 (hu)
TW (1) TW224053B (hu)
WO (1) WO1993005806A1 (hu)
ZA (1) ZA926964B (hu)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (hu) * 1991-09-13 1994-05-21 Paul B Chretien
WO1995011688A1 (en) * 1992-02-06 1995-05-04 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
WO1994001125A1 (en) * 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
DK0731710T3 (da) * 1993-11-05 2003-06-16 Sciclone Pharmaceuticals Inc Fremgangsmåde og præparat til behandling af patienter med inkompenseret leversygdom
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
KR100394382B1 (ko) * 1996-02-28 2004-02-05 유니하트 코포레이션 천연사람α-인터페론으로구성된약학조성물
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
DK1311279T3 (da) * 2000-08-07 2007-02-12 Sciclone Pharmaceuticals Inc Behandling af hepatitis C med thymosin, interferon og ribavirin
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US20050013801A1 (en) * 2001-10-05 2005-01-20 Hsu Henry H. Methods of treating liver fibrosis and hepatitis c virus infection
BR0213554A (pt) * 2001-10-26 2004-10-26 Rhode Island Hospital Timosina para aumento da imunização genética
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004002999A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
CA2509687C (en) 2002-12-12 2012-08-14 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
DE602004027127D1 (de) * 2003-03-28 2010-06-24 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
BRPI0408892A (pt) 2003-03-28 2006-04-11 Sciclone Pharmaceuticals Inc uso de timosina alfa 1 para tratar as infecções por arpergillus
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
PL1658302T3 (pl) 2003-07-25 2011-03-31 Idenix Pharmaceuticals Inc Analogi nukleozydów purynowych do leczenia chorób spowodowanych przez Flaviviridae obejmujących zapalenie wątroby typu C
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
RU2433124C2 (ru) 2004-09-14 2011-11-10 Фармассет, Инк. Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
JP5254033B2 (ja) 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8337828B2 (en) * 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2349315A4 (en) * 2008-10-08 2012-07-04 Univ Miami LYMPHOCYTE REGULATION AND APPLICATION
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (hu) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
GR3024025T3 (en) 1997-10-31
FI941133A0 (fi) 1994-03-10
ATE152914T1 (de) 1997-05-15
NO941310D0 (no) 1994-04-12
RO111991B1 (ro) 1997-04-30
HK1021687A1 (en) 2000-06-23
HU221006B1 (hu) 2002-07-29
HUT75166A (en) 1997-04-28
DK0603305T3 (da) 1997-09-01
RU2104010C1 (ru) 1998-02-10
ES2103966T3 (es) 1997-10-01
EP0603305B1 (en) 1997-05-14
TW224053B (hu) 1994-05-21
EP0603305A1 (en) 1994-06-29
CA2119006C (en) 2005-08-23
KR100254082B1 (ko) 2000-09-01
ZA926964B (en) 1993-04-26
US6001799A (en) 1999-12-14
US20070218033A1 (en) 2007-09-20
WO1993005806A1 (en) 1993-04-01
DE69219782D1 (de) 1997-06-19
MX9205240A (es) 1993-07-01
CZ286827B6 (cs) 2000-07-12
CA2119006A1 (en) 1993-04-01
DE69219782T2 (de) 1997-10-09
HU9400758D0 (en) 1994-06-28
RU94022480A (ru) 1996-07-20
SG64897A1 (en) 1999-05-25
AU2644792A (en) 1993-04-27
NO941310L (no) 1994-04-12
FI941133A (fi) 1994-03-10
AU667327B2 (en) 1996-03-21
CZ55194A3 (en) 1994-10-19
JPH06510998A (ja) 1994-12-08
US5849696A (en) 1998-12-15
JP3228512B2 (ja) 2001-11-12

Similar Documents

Publication Publication Date Title
FI107879B (fi) Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi
Grüngreiff et al. Serum concentrations of sIL-2R, IL-6, TGF-β1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha
CA2236591C (en) Continuous low-dose cytokine infusion therapy
Lok et al. Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection
Pockros Developments in the treatment of chronic hepatitis C
Artillo et al. Double‐blind, randomized controlled trial of interleukin‐2 treatment of chronic hepatitis B
Douglas et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM
EP0687181B1 (en) Use of thymosin for treating hepatitis c in non-responders to interferon treatment
WO1994001125A1 (en) Composition and method of treating hepatitis b
WO1994001125A9 (en) Composition and method of treating hepatitis b
Ruiz-Moreno et al. Levamisole and interferon in children with chronic hepatitis B
Kagawa et al. A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C
Moskovitz et al. High Dose Consensus Interferon in Nonresponders to Interferon Alpha‐2B and Ribavirin with Chronic Hepatitis C
JPH07258109A (ja) Ｃ型肝炎の処置法および処置用組成物
Hwang et al. A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C
Zhang Pegylated interferons in the treatment of chronic hepatitis C
Bosch et al. Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole
AU751199B2 (en) Composition and method of treating hepatitis B
WO1993020835A1 (en) Treatment of hepatitis with gm-csf
Pockros Current status of immunomodulatory therapies in HCV infection

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ALPHA 1 BIOMEDICALS, INC.

GB Transfer or assigment of application

Owner name: ALPHA 1 BIOMEDICALS, INC.

MM Patent lapsed